Randomized, placebo-controlled study of Tiratricol in Allan-Herndon-Dudley syndrome in treated patients
Latest Information Update: 23 Aug 2022
At a glance
- Drugs Tiratricol (Primary)
- Indications Allan-Herndon-Dudley syndrome
- Focus Therapeutic Use
Most Recent Events
- 19 Aug 2022 According to an Egetis Therapeutics media release, in dialogue with the FDA, the company has finalized the protocol for this study, which is expected to start in the autumn of 2022.
- 28 Jan 2022 New trial record
- 27 Jan 2022 According to an Egetis Therapeutics media release, the company planning to conduct this study before submission for a New Drug Application in the US under the granted Fast Track Designation targeted in mid-2023.